leadf
logo-loader
viewGenprex, Inc.

Genprex appoints Dr William Gannon as the company’s vice president of Regulatory Affairs

Gannon will be responsible for managing the company’s regulatory affairs for its upcoming clinical trials that combine its lead drug candidate, GPX-001 for non-small cell lung cancer (NSCLC), with AstraZeneca’s targeted therapy Tagrisso (osimertinib) and with immunotherapy Keytruda (pembrolizumab)

Genprex, Inc. -
He currently serves as chief scientific officer and medical director at Capital City Technical Consulting

Genprex, Inc. (NASDAQ:GNPX) has announced the appointment of William Gannon, MD, MBA as the company’s vice president of Regulatory Affairs.

The clinical-stage gene therapy company, which is developing potentially life-changing technologies for patients with cancer and diabetes, noted that Dr Gannon brings more than 30 years of experience in the biotech and pharmaceutical industries to the company, with expertise in clinical development, regulatory affairs and commercialization of products, and a strong background in oncology and gene therapy.

READ: Genprex gets price target bump, repeat Outperform rating from Noble Capital analysts

In a statement, Rodney Varner, Genprex’s chairman and chief executive officer said: “We are pleased to have Dr. Gannon join our team. His extensive experience in the management of clinical trials, from designing trials to building operational teams, will be an important asset for us as we work toward initiating our upcoming trials and seeing them through to successful completion.”

Dr Gannon will be responsible for managing the company’s regulatory affairs for its upcoming clinical trials that combine its lead drug candidate, GPX-001 for non-small cell lung cancer (NSCLC), with AstraZeneca’s targeted therapy Tagrisso (osimertinib) and with immunotherapy Keytruda (pembrolizumab).

In January, Genprex received Fast Track Designation from the US Food and Drug Administration (FDA) for use of GPX-001 in combination with Tagrisso in late-stage lung cancer patients with EGFR mutations whose tumors progress on Tagrisso.

Alongside his responsibility of advising on regulatory matters, Dr Gannon will also serve as the Medical Monitor, interfacing with medical personnel at trial sites and assisting with FDA communication throughout the clinical trials.

He currently serves as chief scientific officer and medical director at Capital City Technical Consulting, where he has led clinical trial development and operations management for various clients across the biotech and pharmaceutical industries and through which he will carry out his new Genprex role.

Prior to Capital City, Dr Gannon served as vice president of Clinical and Medical Affairs for Celsion Corporation, an oncology biotech and medical device firm, where he led its clinical trial development and operations, data management, regulatory affairs and FDA submissions.

He has held several executive roles at various biotech, pharmaceutical and medical device companies, overseeing regulatory affairs, both US and international, for filings, meetings, submissions and approvals. He has served on the Institutional Review Board (IRB), Board of Directors and Clinical Advisory Board of several organizations and is an active member of research and professional affiliations.

Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options.

Contact the author at [email protected]

Quick facts: Genprex, Inc.

Price: 3.25 USD

NASDAQ:GNPX
Market: NASDAQ
Market Cap: $126.33 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Genprex reveals slew of recent milestones as it plans for upcoming clinical...

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner talks to Proactive's Christine Corrado about the Texas-based biotechnology company's most recent updates. Namely, Varner says the firm has approved the generic name quaratusugene ozeplasmid, for its non-small cell lung cancer drug formerly known as...

on 07/02/2020

3 min read